Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

Our Products
Overview
Partnering Search
Company Profiling
Partneringtools
Reports
Partnering Consulting
Comparison
 
Forums
Visit our forums
 
Jobs
Visit our job site
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire New!
 
Contact us
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing Ltd
is a division of
UTEK Corporation
Out-licensing

Kortos® Cream and Kortos® HC Cream For the treatment of acute hemorrhoids, anal fissure and anal pruritus.

Kortos® Cream contains anti-inflammatory-antipruritic-vasoconstrictor, astringent, antiseptic and local anesthetic in a special water repellant base.

Mechanism of action

Kortos® Antihemorrhoidal Cream contains active agents in a vehicle containing Dimethicone which protects against maceration by repelling water while allowing the skin to breathe.

Full description

Kortos® HC Cream contains hydrocortisone acetate 0.5% (low potency topical corticosteroid) which reduces itching, inflammation and discomfort by vasoconstriction, lysosomal membrane stabilization and antimitotic activity; benzocaine 2.5% (local anesthetic) which relieves pain, burning, itching, discomfort and irritation in the anorectal area by preventing the transmission of nerve impulses; bismuth subgallate, 2% (astringent) which coagulates the protein in skin cells, thereby protecting the underlying tissue and decreasing the cell volume. It also lessens mucus and other secretions and helps relieve local anorectal irritation and inflammation; benzalkonium chloride 0.1% (antiseptic) inhibits growth of microorganisms in the anorectal region.

Kortos® Cream contains all the same ingredients as Kortos® HC Cream with the exception of Hydrocortisone Acetate. Kortos® Cream contains Dimethicone, which protects the anorectal area against maceration and provides a longer lasting action by preventing loss (or leakage) of active substances from the application site by forming a hydrophobic layer between the skin and water. A study, in healthy human volunteers, of tolerance to Kortos® Cream has been carried out in the UK, which showed the cream to be well tolerated and not causing any significant changes in vital signs and devoid of significant systemic or local side/adverse effects. Therapeutic indications: Kortos® Cream and Kortos®HC Cream are indicated for the symptomatic treatment of internal and external acute hemorrhoids, anal fissure and anal pruritus. Kortos® Cream and Kortos®HC Cream are supplied in 30gm Laminated tubes with rectal applicator.

Development status

Registered

Patent information

Licensed in Turkey since 1997.

Type of business relationship sought

Licensing partners sought worldwide.

Partnering consultation free of charge
Tech Transfer Summit
Yissum Technology Transfer Hebrew University
Industry news: Pharmalicensing provides comprehensive industry coverage.

© Copyright 1995-2008 Pharmalicensing Ltd, is a division of UTEK Corporation All rights reserved. Terms and Conditions | Site map | Contact us